Have a personal or library account? Click to login
Soluble urokinase-type plasminogen activator receptor (suPAR) – a possible biomarker for bacteremia in sepsis / Forma solubilă a receptorului pentru activatorul de plasminogen de tip urokinază (suPAR) – un biomarker posibil pentru bacteriemie în sepsis Cover

Soluble urokinase-type plasminogen activator receptor (suPAR) – a possible biomarker for bacteremia in sepsis / Forma solubilă a receptorului pentru activatorul de plasminogen de tip urokinază (suPAR) – un biomarker posibil pentru bacteriemie în sepsis

Revista Romana de Medicina de Laborator
Volume 23 (2015): Issue 1 (March 2015)
By: Anca-Meda Georgescu,  Janos Szederjesi,  Septimiu Voidăzan,  Minodora Dobreanu,  Sanda Maria Copotoiu,  Adina Huțanu and  Leonard Azamfirei  
Open Access
|Mar 2015

References

  1. 1. Dellinger RH, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Sur-viving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013. Feb;41(2):580-637.10.1097/CCM.0b013e31827e83af23353941
    Search in Google Scholar
  2. 2. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knauss WA, et al. Defini-tions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/ Society of Critical Care Medicine. Chest. 1992 Jun;101(6):1644-55. DOI: 10.1378/chest.101.6.164410.1378/chest.101.6.16441303622
    Search in Google Scholar
  3. 3. Matzinger P. The danger model: a renewed sense of self. Science. 2002 Apr 12;296(5566):301-5. DOI: 10.1126/science.107105910.1126/science.107105911951032
    Search in Google Scholar
  4. 4. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, et al. Circulating mito-chondrial DAMPs cause inflammatory responses to injury. Nature. 2010 Mar 4;464(7285):104-7. DOI: 10.1038/nature0878010.1038/nature08780284343720203610
    Search in Google Scholar
  5. 5. Jones GR, Lowes JA. The systemic inflammatory response syndrome as a predic-tor of bacteremia and outcome from sepsis. QJM.1996 Jul;89(7):515-22. DOI: 10.1093/qjmed/89.7.51510.1093/qjmed/89.7.5158759492
    Search in Google Scholar
  6. 6. Bates DW, Sands K, E. Miller E, Lanken PN, Hibberd PL, Graman PS, et al. Pre-dicting bacteremia in patients with sepsis syndrome. Academic Medical Center Consortium Sepsis Project Working Group. J Infect Dis. 1997 Dec;176(6):1538-51. DOI: 10.1086/51415310.1086/5141539395366
    Search in Google Scholar
  7. 7. Bauer M, Reinhart K. Molecular diagnostics of sepsis-- where are we today? Int J Med Microbiol. 2010 Aug;300(6):411-3. DOI: 10.1016/j.ijmm.2010.04.00610.1016/j.ijmm.2010.04.00620510650
    Search in Google Scholar
  8. 8. Loonen AJM, de Jager CPC, Tosserams J, Kusters R, Hilbink M, Wever PC, et al. Biomarkers and molecular analysis to improve bloodstream infection diagnostics in an emergency care unit. PLoS ONE 2014. Jan; 9(1):e87135. DOI: 10.1371/journal.pone.008731510.1371/journal.pone.0087315390362324475269
    Search in Google Scholar
  9. 9. Reinhart K, Bauer M, Riedermann NC, Hartog CS. New approaches to sepsis: molecular diagnostics and biomarkers. Clin Microbiol Rev. 2012 Oct;25(4):609-34 DOI: 10.1128/CMR.00016-1210.1128/CMR.00016-12348575123034322
    Search in Google Scholar
  10. 10. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit. Care. 2010;14(1):R15. DOI: 10.1186/cc887210.1186/cc8872287553020144219
    Search in Google Scholar
  11. 11. Riisbro R, Christensen IJ, Hogdall C, Brunner N, Hogdall E. Soluble urokinase plasminogen activator receptor measurements: influence of sample handling. Int J Biol Markers. 2001 Oct-Dec;16(4):233-9.10.1177/172460080101600402
    Search in Google Scholar
  12. 12. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/ SIS International Sepsis Definitions Conference. Crit Care Med. 2003 Apr;31(4):1250-6. DOI: 10.1097/01. CCM.0000050454.01978.3B10.1097/01
    Search in Google Scholar
  13. 13. Hatzistilianou M. Diagnostic and prognostic role of procalcitonin in infections. ScientificWorldJournal. 2010 Oct;10:1941-6. DOI: 10.1100/tsw.2010.18110.1100/tsw.2010.181
    Search in Google Scholar
  14. 14. Uzzan B, Cohen R, Nicolas P, Cucherat P, Perret GY. Procalcitonin as a diagnos-tic test for sepsis in critically ill adults and after surgery or trauma: a systematic re-view and meta-analysis. Crit Care Med. 2006 Jul;34(7):1996-2003. DOI: 10.1097/01. CCM.0000226413.54364.3610.1097/01
    Search in Google Scholar
  15. 15. Bloos F. Clinical diagnosis of sepsis and the combined use of biomarkers and culture and non-culture-based assays. Methods Mol Biol. 2015;1237:247-60. DOI: 10.1007/978-1-4939-1776-1_1910.1007/978-1-4939-1776-1_19
    Search in Google Scholar
  16. 16. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993 Feb 27;341(8844):515-8. DOI: 10.1016/0140-6736(93)90277-N10.1016/0140-6736(93)90277-N
    Search in Google Scholar
  17. 17. Bopp C, Hofer S, Bouchon A, Zimmermann JB, Martin E, Weigand MA. Soluble TREM-1 is not suitable for distinguishing between systemic inflammatory re-sponse syndrome and sepsis survivors and nonsurvivors in the early stage of acute inflammation. Eur J Anaesthesiol. 2009 Jun;26(6):504-7. DOI: 10.1097/ EJA.0b013e328329afca10.1097/EJA.0b013e328329afca19307971
    Search in Google Scholar
  18. 18. Povoa P, Teixeira-Pinto AM, Carneiro AH, Portuguese Community-Acquired Sepsis Study Group SACiUCI. C-reactive protein, an early marker of community-acquired sepsis resolution: a multi-centre prospective observational study. Crit Care. 2011 Jul;15(4):R169. DOI: 10.1186/cc1031310.1186/cc10313338760921762483
    Search in Google Scholar
  19. 19. Suberviola B, Castellanos-Ortega A, Ruiz Ruiz A, Lopez- Hoyos M, Santibanez M. Hospital mortality prognostication in sepsis using the new biomarkers suPAR and proADM in a single determination on ICU admission. Intensive Care Med. 2013 Sep; 39(9):1945-52. DOI: 10.1007/s00134-013-3056-z10.1007/s00134-013-3056-z23949703
    Search in Google Scholar
  20. 20. Schuetz P, Christ-Crain M, Muller B. Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections - hope for hype? Swiss Med Wkly. 2009 Jun;139(23-24):318-26.
    Search in Google Scholar
  21. 21. Huttunen R, Syrjanen J, Vuento R, Hurme M, Huhtala H, Laine J, et al. Plasma level of soluble uroki nase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteremia: a prospective cohort study. J Intern Med. 2011 Jul;270(1):32-40. DOI: 10.1111/j.1365-2796.2011.02363.x10.1111/j.1365-2796.2011.02363.x21332843
    Search in Google Scholar
  22. 22. Georgescu AM, Azamfirei L. Cell receptors as biomarkers in sepsis pathology. J Rom Anest Terap Int. 2014 April;21(1):45-52.
    Search in Google Scholar
  23. 23. Andersen O, Eugen-Olsen J, Kofoed K, Iversen J, Haugaard SB. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected pa-tients receiving highly active antiretroviral therapy. J Med Virol. 2008 Feb; 80(2):209-16. DOI: 10.1002/ jmv.2111410.1002/jmv.2111418098145
    Search in Google Scholar
  24. 24. Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, car-diovascular disease, diabetes and mortality in the general population. J Intern Med. 2010 Sep; 268(3):296-308. DOI: 10.1111/j.1365-2796.2010.02252.x10.1111/j.1365-2796.2010.02252.x20561148
    Search in Google Scholar
  25. 25. Eugen-Olsen J. suPAR - a future risk marker in bacteremia. J Intern Med. 2011 Jul; 270(1):29-31. DOI: 10.1111/j.1365-2796.2011.02372.x10.1111/j.1365-2796.2011.02372.x21366732
    Search in Google Scholar
  26. 26. Backes Y, van der Sluijs KF, Mackie DP, Tacke F, Koch A, Tenhunen JJ. et al. Use-fulness of suPAR as a biological marker in patients with systemic inflammation or in-fection: a systematic review. Intensive Care Med. 2012 Sep; 38(9):1418-28. DOI: 10.1007/s00134-012-2613-110.1007/s00134-012-2613-1342356822706919
    Search in Google Scholar
  27. 27. Koch A, Voigt S, Kruschinski C, Sanson E, Dückers H, Horn A, et al. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill pa-tients. Crit Care. 2011; 15(1):R63. DOI: 10.1186/cc1003710.1186/cc10037322199621324198
    Search in Google Scholar
  28. 28. Donadello K, Scolletta S, Covajes C, Vincent JL. suPAR as a prognostic biomarker in sepsis. BMC Med. 2012 Jan;5:10:2. DOI: 10.1186/1741-7015-10-210.1186/1741-7015-10-2327554522221662
    Search in Google Scholar
  29. 29. Siahanidou T, Margeli A, Tsirogianni C, Charoni S, Giannaki M, Vavourakis E, et al. Clinical value of plasma soluble urokinase-type plasminogen activator receptor levels in term neonates with infection or sepsis: a prospective study. Mediators Inflamm. 2014 May;2014:375702.10.1155/2014/375702402698924882949
    Search in Google Scholar
  30. 30. Donadello K, Scolletta S, Taccone FS, Covajes C, Santonocito C Cortes DO, et al. Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients. J Crit Care. 2014 Feb; 29(1):144-9. DOI: 10.1016/j.jcrc.2013.08.00510.1016/j.jcrc.2013.08.00524120089
    Search in Google Scholar
  31. 31. Koch A, Tacke F. Why high suPAR is not super-diagnostic prognostic and potential pathogenic properties of a novel biomarker in the ICU. Crit Care. 2011 Dec;15(6):1020. DOI: 10.1186/cc1057710.1186/cc10577338868822182777
    Search in Google Scholar
  32. 32. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003 Apr;348(16):1546-54 DOI: 10.1056/NEJMoa02213910.1056/NEJMoa02213912700374
    Search in Google Scholar
  33. 33. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006 Feb;34(2):344-53. DOI: 10.1097/01. CCM.0000194725.48928.3A10.1097/01
    Search in Google Scholar
  34. 34. Samraj RS, Zingarelli B, Wong HR. Role of biomarkers in sepsis care. Shock. 2013 Nov;40(5):358-65. DOI: 10.1097/SHK.0b013e3182a66bd610.1097/SHK.0b013e3182a66bd6380604724088989
    Search in Google Scholar
  35. 35. Marshall JC, Reinhart K. International Sepsis Forum. Biomarkers of sepsis. Crit Care Med. 2009 Jul;37(7):2290-8. DOI: 10.1097/CCM.0b013e3181a02afc10.1097/CCM.0b013e3181a02afc19487943
    Search in Google Scholar
  36. 36. Pisinger C, Ladelund S, Eugen-Olsen J. Influence of Lifestyle on suPAR Levels. The Inter99 Study; 2012 [http://suparnostic.com/images/stories/3rd_supar_symposium_2012_abstracts_program.pdf:11-11]
    Search in Google Scholar
  37. 37. Haugaard SB, Andersen O, Hansen TW, Eugen-Olsen J, Linneberg A, Madsbad S, et al. The immune marker soluble urokinase plasminogen activator receptor is associated with new-onset diabetes in non-smoking women and men. Diabet Med. 2012 Apr;29(4):479-87. DOI: 10.1111/j.1464-5491.2011.03513.x10.1111/j.1464-5491.2011.03513.x22050462
    Search in Google Scholar
  38. 38. http://suparnostic.com/Result-Interpretation. [Accessed on Sep 20th, 2012].
    Search in Google Scholar
  39. 39. Lodes U, Bohmeier B, Lippert H, Konig B, Meyer F. PCR-based rapid sepsis di-agnosis effectively guides clinical treatment in patients with new onset of SIRS. Langenbecks Arch Surg. 2012 (Mar);397(3):447-55. DOI: 10.1007/s00423-011-0870-z10.1007/s00423-011-0870-z22109826
    Search in Google Scholar
  40. 40. Hoenigl M, Raggam RB, Wagner J, Valentin T, Leitner E, Seeber K, et al. Diag-nostic accuracy of soluble urokinase activator receptor (suPAR) for prediction of bacteremia in patients with systemic inflammatory response syndrome. Clin Bio-chem. 2013 Feb;46(3):225-9. DOI: 10.1016/j.clinbiochem.2012.11.00410.1016/j.clinbiochem.2012.11.00423159293
    Search in Google Scholar
  41. 41. Yilmaz G, Koksal I, Karahan SC, Mentese A. The diagnostic and prognostic significance of soluble urokinase plasminogen activator receptor in systemic in-flammatory response syndrome. Clin Biochem. 2011 Oct;44(14-15):1227-30. DOI: 10.1016/j.clinbiochem. 2011.07.006
    Search in Google Scholar
  42. 42. Wittenhagen P, Kronborg G, Weis N, Nielsen H, Obel N, Pedersen SS, et al. The plasma level of soluble urokinase receptor is elevated in patients with Streptococ- cus pneumoniae bacteraemia and predicts mortality. Clin Microbiol Infect 2004 May; 10(5):409-15. DOI: 10.1111/j.1469-0691.2004.00850.x10.1111/j.1469-0691.2004.00850.x15113317
    Search in Google Scholar
  43. 43. Meijers B, Poesen R, Claes K, Dietrich R, Bammens B, Sprangers B, et al. Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease. Kidney Int. 2015 Jan;87(1):210-6. DOI: 10.1038/ ki.2014.19710.1038/ki.2014.19724897037
    Search in Google Scholar
  44. 44. Kofoed K, Eugen-Olsen J, Petersen J, Larsen K, Andersen O. Predicting mortality in patients with systemic inflammatory response syndrome: an evaluation of two prognostic models, two soluble receptors, and a macrophage migration inhibitory factor. Eur J Clin Microbiol Infect Dis. 2008 May;27(5):375-83. DOI: 10.1007/ s10096-007-0447-510.1007/s10096-007-0447-518197443
    Search in Google Scholar
  45. 45. Kofoed K, Andersen O, Kronborg G, Tvede M, Petersen J, Eugen-Olsen J, et al. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migra-tion inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diag-nose infections: a prospective study. Crit Care. 2007;11(2):R38. DOI: 10.1186/cc572310.1186/cc5723220645617362525
    Search in Google Scholar
  46. 46. Raggam RB, Wagner J, Pruller F, Grisold A, Leitner E, Zollner-Schwetz I, et al. Soluble urokinase plasminogen activator receptor predicts mortality in patients with systemic inflammatory response syndrome. J Inter Med. 2014 Mar;19. DOI: 10.1111/joim.1223810.1111/joim.1223824645798
    Search in Google Scholar
  47. 47. Molkanen T, Ruotsalainen E, Thorball CW, Jarvinen A. Elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococus aure-us bacteremia. Eur J Clin Microbiol Infect Dis. 2011 Nov;30(11):1417-24. DOI: 10.1007/s10096-011-1236-810.1007/s10096-011-1236-821479972
    Search in Google Scholar
  48. 48. Moller HJ, Moestrup SK, Weis N, Wejse C, Nielsen H, Pedersen SS, et al. Macro-phage serum markers in pneumococcal bacteremia: prediction of survival by solu-ble CD163. Crit Care Med. 2006 Oct;34(10):2561-6. DOI: 10.1097/01.CCM.0000239120.32490.AB10.1097/01.CCM.0000239120.32490.AB16915112
    Search in Google Scholar
  49. 49. Kaya S, Köksal I, Menteşe A, Sönmez M, Sümer A, Yıldırım SS, et al. The signi-ficance of serum urokinase plasminogen activation receptor (suPAR) in the di-agnosis and follow-up of febrile neutropenic patients with hematologic malignan-cies. Int J Infect Dis. 2013 Nov;17(11):e1056-9. DOI: 10.1016/j.ijid.2013.04.004 10.1016/j.ijid.2013.04.00423742830
    Search in Google Scholar
DOI: https://doi.org/10.1515/rrlm-2015-0002 | Journal eISSN: 2284-5623 | Journal ISSN: 1841-6624
Journal RSS Feed
Language: English
Page range: 59 - 73
Submitted on: Nov 18, 2014
|
Accepted on: Jan 18, 2015
|
Published on: Mar 25, 2015
Published by: Romanian Association of Laboratory Medicine
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Sepsis,
suPAR,
biomarkers,
bacteremia,
mortality
Related subjects:
Life sciences,
Molecular biology,
Biochemistry,
Human biology,
Microbiology and virology

© 2015 Anca-Meda Georgescu, Janos Szederjesi, Septimiu Voidăzan, Minodora Dobreanu, Sanda Maria Copotoiu, Adina Huțanu, Leonard Azamfirei, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 23 (2015): Issue 1 (March 2015)Next article